[Evaluation model of the effect of Rofecoxib on the co-prescriptionof gastroprotective agents observed during the treatment of osteoarthritis].

Abstract

This study was conducted to define an evaluation model to estimatechanges in the co-prescription of gastroprotective agents (GPAs)induced by rofecoxib in the treatment of osteoarthritis (OA).

Publication
Reumatismo